Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2023 >

Decisions 27th June 2023

New Drug Requests

Approved

Methoxyflurane (inhaled) (Penthrox®) (TLS Red)

  •  For pain relief for brachytherapy applicator removal and pre-radiotherapy rectal spacer insertion

 Methoxyflurane (inhaled) (Penthrox®(TLS Red)

  • For pain relief for painful dressings changes for patients with painful leg ulcers who require rapid onset analgesia for a short duration

Itulazax (Standardised allergen extract of pollen from white birch [Betula verrucosa]) (TLS Red)

  • For treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group for use by the specialist allergy team.

Beclometasone / Formoterol / Glycopyrronium (Trimbow® pMDI 172/5/9) (TLS Blue)

  • For maintenance treatment of asthma

 

Shared Care Protocols

  • Nil

 

Traffic Light Status Change Requests

  • Nil 

 

Other Formulary Decisions

  • The BNSSG SCP Review Process was approved

 

Further Work

Biologics and Apremilast for psoriasis update- further work needed 

  • The new drug request application for biologics (adalimumab, infliximab, etanercept, tildrakizumab, certolizumab, risankizumab, guselkumab, brodalumab, ixekizumab, secukinumab, bimekizumab, ustekinumab) and apremilast for severe psoriasis at localised, high impact sites was discussed by the Joint Formulary Group. Further work is needed before any changes can be made to the current formulary position including financial considerations and update to the psoriasis biologics pathway. The current formulary position remains in place until this work is complete.